We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

43 hedge funds and large institutions have $2.79M invested in Galectin Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

274% more call options, than puts

Call options by funds: $86K | Put options by funds: $23K

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

9.7% more ownership

Funds ownership: 0% → 9.7% (+9.7%)

7% less funds holding

Funds holding: 46 → 43 (-3)

19% less capital invested

Capital invested by funds: $3.43M → $2.79M (-$639K)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
7
Closed
8
Calls
$86K
Puts
$23K
Net Calls
+$63K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
DADC
D.A. Davidson & Co
Montana
+$108K
2
BCA
Benchmark Capital Advisors
New York
+$71.1K
3
ARTA
A.R.T. Advisors
New York
+$28.2K
4
LWAC
Laurel Wealth Advisors (California)
California
+$8.89K
5
BFA
BlackRock Fund Advisors
California
+$2.09K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$158K
2
SM
Sabby Management
Florida
-$78.2K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$55.7K
4
AG
Advisor Group
Arizona
-$37.6K
5
Wolverine Trading
Wolverine Trading
Illinois
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
DADC
1
D.A. Davidson & Co
Montana
$709K +$108K +121,692 +20%
Vanguard Group
2
Vanguard Group
Pennsylvania
$516K -$55.7K -62,682 -11%
AG
3
Advisor Group
Arizona
$363K -$37.6K -42,300 -10%
BCA
4
Benchmark Capital Advisors
New York
$194K +$71.1K +80,000 +68%
CCM
5
Courage Capital Management
Tennessee
$127K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$106K +$459 +516 +0.5%
Neuberger Berman Group
7
Neuberger Berman Group
New York
$91K – – –
US Bancorp
8
US Bancorp
Minnesota
$89K – – –
VKH
9
Virtu KCG Holdings
New York
$83K -$14.5K -16,355 -16%
BFA
10
BlackRock Fund Advisors
California
$80K +$2.09K +2,356 +3%
GWM
11
Geneos Wealth Management
Colorado
$51K +$1.6K +1,800 +4%
Northern Trust
12
Northern Trust
Illinois
$44K +$1.76K +1,978 +5%
BIT
13
BlackRock Institutional Trust
California
$41K – – –
CCB
14
Cutter & Co Brokerage
Missouri
$35K -$3.11K -3,500 -9%
ARTA
15
A.R.T. Advisors
New York
$31K +$28.2K +31,740 New
NPF
16
Norris Perne & French
Michigan
$30K – – –
JMPWA
17
JP Morgan Private Wealth Advisors
California
$25K – – –
SWP
18
Stratos Wealth Partners
Ohio
$24K – – –
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$23K – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
$22K +$692 +779 +4%
RG
21
Rathbones Group
United Kingdom
$16K – – –
Goldman Sachs
22
Goldman Sachs
New York
$15K +$155 +174 +1%
GC
23
Guggenheim Capital
Illinois
$11K – – –
State Street
24
State Street
Massachusetts
$11K – – –
Bank of America
25
Bank of America
North Carolina
$9K -$2 -2 -0%
1
2

GALT Hedge Fund Activity: Q4 2016 in Review

43 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2016, worth a combined $2.79M — down 19% from $3.43M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GALT and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was D.A. Davidson & Co, adding an estimated $108K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $158K sold.

  • 43 institutional investors held Galectin Therapeutics (GALT) as of Q4 2016, down from 46 in Q3 2016.
  • Funds reported $2.79M of Galectin Therapeutics stock for Q4 2016, down 19% quarter-over-quarter.
  • 6 funds opened new Galectin Therapeutics positions in Q4 2016 and 8 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q4 2016 was D.A. Davidson & Co, an estimated $108K added.
  • The largest Galectin Therapeutics seller in Q4 2016 was Jacobs Levy Equity Management, an estimated $158K sold.

Based on aggregated 13F filings for Q4 2016.